

ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and Gastrointestinal Cancers

PROGRAMME

**ESMO
ADVANCED COURSE**

**ZURICH SWITZERLAND
4-5 OCTOBER 2024**

Co-Chairs

Giuseppe Curigliano, Italy

Elizabeth Smyth, United Kingdom

ESMO ADVANCED COURSE PROGRAMME

ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: BREAST, GYNAECOLOGICAL AND GI CANCERS

Zurich, Switzerland
4-5 October 2024

CO-CHAIRS Giuseppe Curigliano, Italy
Elizabeth Smyth, United Kingdom

SPEAKERS Nicoletta Colombo, Italy
Elisa Fontana, United Kingdom
Maria Fernanda Mosele, France
Barbara Pistilli, France
Giancarlo Pruneri, Italy
Andrea Sartore Bianchi, Italy

LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](https://www.esmo.org).

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 4 October 2024

09:00-09:10 **Welcome and introduction**

10' Welcome and learning objectives
Giuseppe Curigliano, IT and Elizabeth Smyth, UK

09:10-10:40 **Session 1 – ADC Development and pharmacodynamics**

Chair: Giuseppe Curigliano, IT

20' ADC development: What are the considerations in early phase trials?
Maria Fernanda Mosele, FR

20' Mechanisms of action and resistance: ADC internalization and cleavage and mechanisms of resistance
Barbara Pistilli, FR

20' Toxicity: Prediction, identification and treatment
Elisa Fontana, UK

30' Q&A

10:40-11:10 **Coffee break**

11:10-12:10 **Session 2 – Target assessment and rationale for combinations**

Chair: Elizabeth Smyth, UK

20' How to develop rationale combinations and sequencing
Giuseppe Curigliano, IT

20' Considerations from pathology: Biomarker selection, on-target, off-tumour expression, off-target toxicities
Giancarlo Pruneri, IT

20' Q&A

12:10-13:10 **Lunch**

13:10-15:10 **Session 3 – Next generation ADCs**

Chair: Giuseppe Curigliano, IT

20' Developments in ADC constructs including bispecific ADCs
Elisa Fontana, UK

20' Cytokine conjugates
Andrea Sartore Bianchi, IT

20' Q&A

20' Peptide-based conjugates
Elizabeth Smyth, UK

20' Therapeutic index and rationale for ADCs sequencing
Barbara Pistilli, FR

20' Q&A

15:10-15:40 **Coffee break**

19:30 **Networking dinner**

Saturday, 5 October 2024

09:00-12:30

Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

Workshop 1

60'

ADC trials in breast cancer

Giuseppe Curigliano, IT

Workshop 2

60'

ADC trials in gastrointestinal cancers

Elizabeth Smyth, UK

Workshop 3

60'

ADC trials in gynecological cancers

Nicoletta Colombo, IT

11:00-11:30

Coffee break

11:30-12:30

Workshops continuation

12:30-13:00

Feedback on the workshops from each group

13:00-13:15

Synthesis and wrap-up

Giuseppe Curigliano, IT and Elizabeth Smyth, UK

13:15-14:15

Lunch